Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610001093077
Ethics application status
Approved
Date submitted
10/12/2010
Date registered
13/12/2010
Date last updated
21/11/2011
Type of registration
Prospectively registered
Titles & IDs
Public title
Comparison of THVD-201 with Tolterodine and Placebo for Overactive Bladder Symptoms
Query!
Scientific title
Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms
(Protocol No.: THVD-201-002)
Query!
Secondary ID [1]
253265
0
THVD -201-002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Symptoms of overactive bladder.
258796
0
Query!
Condition category
Condition code
Renal and Urogenital
258947
258947
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
THVD-201, a Combination of Tolterodine and a Muscarinic Agonist
Lead in period = 6 weeks duration: Toterodine 2 mg twice daily.
12 week double blind period where patients receive either of the following: THVD-201 twice daily; Tolterodine 2 mg twice daily; or Placebo twice daily. There are three periods of four weeks duration. Patients either take one of the three doses for 4 weeks and then cross over to either of the other two treatments at four weekly intervals.
Extension period (12 weeks duration): Either, 4mg Tolterodine long acting once daily; or 3 mg THVD-201 twice daily.
Query!
Intervention code [1]
257729
0
Treatment: Drugs
Query!
Comparator / control treatment
In the double blind phase the comparator is Tolterodine 2mg twice daily verses the study drug verses placebo.
In the extension phase the comparator is 4mg Tolterodine (long acting) verses 3mg THVD-201 (twice daily).
12 week double blind period where patients receive either of the following: THVD-201 twice daily; Tolterodine 2 mg twice daily; or Placebo twice daily. There are three periods of four weeks duration. Patients either take one of the three doses for 4 weeks and then cross over to either of the other two treatments at four weekly intervals.
Extension period (12 weeks duration): Either, 4mg Tolterodine long acting once daily; or 3 mg THVD-201 twice daily.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
259799
0
Determine the tolerability of the combination of tolterodine and pilocarpine (THVD-201) in OAB subjects.
Query!
Assessment method [1]
259799
0
Query!
Timepoint [1]
259799
0
A subject diary will be completed documenting the average daily number of micturitions; the average daily number of incontinence episodes and the average daily VAS scores of dry mouth at baseline, Week 4, Week 8 and Week 12 of the double blind period and week 6 and week 12 in the open label extension period.
Query!
Secondary outcome [1]
268599
0
Determine the effect of THVD 201 vs tolterodine alone vs. placebo on the symptoms of overactive bladder in subjects who have some degree of dry mouth on toterodine monotherapy.
Query!
Assessment method [1]
268599
0
Query!
Timepoint [1]
268599
0
A subject diary will be completed documenting the average daily number of micturitions; the average daily number of incontinence episodes and the average daily VAS scores of dry mouth at baseline, Week 4, Week 8 and Week 12 of the double blind period and week 6 and week 12 in the open label extension period.
Query!
Eligibility
Key inclusion criteria
1. Females 18-75 years
2. Subject has a history of OAB (pure urge or mixed urinary incontinence with predominant urge incontinence) for equal to 6 months.
Subject who is currently taking IR tolterodine (2 mg bid) for at least 5 weeks and who is considered to be a responder to this therapy (see below for number of micturitions and incontinence episodes per day). Depending on the anti-muscarinic treatment at screening, all subjects will need to have completed at least 1 to 5 weeks of 2 mg bid IR tolterodine prior to starting the baseline diary o Subjects may be converted from extended release tolterodine (at least 4 weeks of 4 mg QD) to tolterodine IR (2 mg bid) for at least 1 week prior to the start of the baseline diary.
Subjects may be converted from a non-tolterodine OAB treatment to IR tolterodine (2 mg bid) for at least 5 weeks prior to initiation of the baseline diary.
Subjects taking IR tolterodine 1 mg bid need to be treated with 2 mg bid tolterodine for at least 5 weeks prior to starting the baseline diary.
3. Subject meets the following criteria, based on the voiding and dry mouth VAS diary
Urinary frequency less than 13 micturitions per day, as recorded in the subject diary with or without symptoms of urgency (i.e., sudden desire to micturate)
Less than 4 incontinence episodes over a 3-day period
VAS equal to or greater than 35 mm on a 100 mm scale for dry mouth
4. Subject is able and willing to correctly and independently complete the subject voiding diaries and VAS assessments for 3 consecutive days during the week before Visits 2, 3, 4 and 5.
5. Subject is able to use toilet without assistance
6. Subject of childbearing potential must have a negative pregnancy test prior to enrollment and should not be breast-feeding. All pre-menopausal subjects must be using a highly effective method of birth control during the study and for at least one month following the last dose of study medication. (Menopause defined as at least one year without menses.) A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1 percent per year) when used consistently and correctly, such as contraceptive implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, or a vasectomized partner.
7. Subject is willing and able to consent to participate by signing an informed consent form following an explanation of the nature and purpose of this study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Subjects with predominate stress incontinence, insensate incontinence (those incapable of distinguishing discrete incontinence episodes) and overflow incontinence, as major reason for urine loss or urinary frequency as determined by the investigator
2. Subjects with history of neurogenic bladder
3. Subjects with clinically significant renal disease (estimated creatinine clearance defined by Cockcroft and Gault formula less than 30 ml per min)
4. Subject has elevated serum transaminases (ALT or AST greater than 1.3 times the upper limit of normal for the laboratory conducting the test) and no history of hepatic dysfunction
5. Subjects with uninvestigated haematuria
6. Subjects who develop acute urinary tract infections (UTI) during the baseline period following a negative urinalysis at screening visit, or subjects with recurrent UTI defined as receiving treatment for symptomatic UTI more than 2 times in the past year
7. Subjects with indwelling catheter or requiring intermittent catheterization
8. Subjects with bladder or lower urinary tract surgeries performed within the past 6 months, or those who had surgeries leading to complications such as fistula
9. Subjects diagnosed with bladder cancer, interstitial cystitis, or painful bladder syndrome within the past 6 months
10. Subjects taking diuretics or oestrogen therapy that was not part of a long-term stable program of at least 6 months
11. Subjects starting bladder retraining per bladder drill programs
12. Subjects who were anticipated to begin or change other bladder therapies (non-medicinal) such as biofeedback or kegels, during the course of the study
13. Subjects with malignancy within the past 6 months or prior pelvic malignancies requiring radiation therapy or whose surgery had led to complications such as fistulas, etc
14. Subjects with a history or presence of tachyarrhythmias or cardiac disease that in the opinion of the investigator might confound the results of the study or pose additional risk to the subject. Subjects with QTc greater than 470 msec should not be enrolled.
15. Subjects taking any medications that may interfere with lower urinary tract function or dry mouth, or affect the subject's suitability and r or effective participation in the trial (i.e., drugs that may have anti-muscarinic or anti-histaminic activity or induce or inhibit cytochrome P450 2D6 enzyme).
16. Subjects with the history or current untreated narrow angle glaucoma
17. Subjects with the history or current myasthenia gravis
18. Subjects with known or suspected biliary tract disease, active nephrolithiasis, cognitive or psychiatric disturbances, gastric retention, urinary retention, uncontrolled ulcerative colitis, toxic megacolon or other known medical condition, which in the opinion of the investigator would compromise the subject’s ability to participate in this trial (e.g., progressive malignant disease, HIV infection, major surgery within last 4 weeks).
19. Subjects with a history of chronic alcohol or drug abuse within last 6 months
20. Subjects with post void residual urine volume > 100 mL (non-invasive bladder scan)
21. Subject with known polyuria (3 L per day)
22. Subjects who drink grapefruit juice daily
23. Subjects with hypersensitivity to the components of the tolterodine and THVD-201 formulation
24. Subjects participating in another clinical trial or receiving a non-approved drug less than 30 days prior to the screening visit.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation involves contacting the holder of the allocation schedule who is "off-site" .
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Three treatment triple crossover
Query!
Phase
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
15/01/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
3082
0
New Zealand
Query!
State/province [1]
3082
0
Query!
Country [2]
3083
0
Korea, Republic Of
Query!
State/province [2]
3083
0
Query!
Funding & Sponsors
Funding source category [1]
258190
0
Self funded/Unfunded
Query!
Name [1]
258190
0
TheraVida, Inc.
Query!
Address [1]
258190
0
400S, El Camino Real Suite 1200
San Mateo, California 94402
Query!
Country [1]
258190
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
TheraVida, Inc
Query!
Address
400S, ElCamino Real Suite 1200
San Mateo, California 94402
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
257365
0
Commercial sector/Industry
Query!
Name [1]
257365
0
Novotech (Australia) Pty Ltd
Query!
Address [1]
257365
0
Level 3 19 Harris Street
Pyrmont, NSW 2009
Query!
Country [1]
257365
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
260181
0
Flinders Clinical Research Ethics Committee
Query!
Ethics committee address [1]
260181
0
Sturt Road, Bedford Park, Adelaide, South Australia
Query!
Ethics committee country [1]
260181
0
Australia
Query!
Date submitted for ethics approval [1]
260181
0
22/10/2010
Query!
Approval date [1]
260181
0
20/11/2010
Query!
Ethics approval number [1]
260181
0
1/10/0428
Query!
Summary
Brief summary
This study will assess the safety of THVD-201 and how well it is tolerated. It will investigate the effects on your bladder symptoms of THVD-201 compared to tolterodine alone, and placebo. The study will also investigate whether the combination treatment reduces the unwanted side effects associated with taking tolterodine alone.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32004
0
Query!
Address
32004
0
Query!
Country
32004
0
Query!
Phone
32004
0
Query!
Fax
32004
0
Query!
Email
32004
0
Query!
Contact person for public queries
Name
15251
0
Andreas Kroemer
Query!
Address
15251
0
Novotech (Australia) Pty Limited
Level 3, 19 Harris Street
Pyrmont, NSW 2009
Query!
Country
15251
0
Australia
Query!
Phone
15251
0
+61 2 8569 1400
Query!
Fax
15251
0
+61 2 8569 1498
Query!
Email
15251
0
[email protected]
Query!
Contact person for scientific queries
Name
6179
0
Mehdi Paborji
Query!
Address
6179
0
TheraVida, Inc.
400 S. El Camino Real Suite 1200
San Mateo, California 94402
Query!
Country
6179
0
United States of America
Query!
Phone
6179
0
+1 650903 2225
Query!
Fax
6179
0
Query!
Email
6179
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF